Efficacy/Safety of Cilnidipine Plus Valsartan Versus Valsartan in Patients With Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 286 participants.

Also called NCT02145104

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 286 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02145104
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02145104. Randomized; double masking; primary purpose treatment. Start 2014-06-17 (actual); primary completion 2016-06-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy/Safety of Cilnidipine Plus Valsartan Versus Valsartan in Patients With Hypertension
Condition
Hypertension
Intervention (Drug)
valsartan 160mg, cilnidipine 10mg, cilinidipine 5mg
Lead sponsor
IlDong Pharmaceutical Co Ltd (class: industry)

Record details

Record id
cardio:ct-nct02145104
Content hash
11c5ff9d1b74e2f3c63fbe4c43bad2d68646b32fe091689e5418b2e66c992360